Lessons From Bluebird Bio: How To Launch Advanced Therapies in Germany

Outcomes-based deals are important for launching cell and gene therapies in Germany, but bluebird bio’s painful experience with Zynteglo shows the importance of the taking the right approach to ensure market success.

German Flag and Map — Zynteglo experience offers lessons on launching ATMPs in Germany • Source: Alamy

The unpalatably low price ultimately awarded to bluebird bio’s gene therapy Zynteglo in Germany and the company’s subsequent decision to withdraw the product from that key European market should serve as lessons to other ATMP manufacturers.

Legal expert Alexander Natz, founder of the Düsseldorf-based law firm Novacos Rechtsanwälte, said companies wanting to launch their own cell or gene therapies in Germany should pay attention to what happened with Zynteglo as Germany is an important first launch market for

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

29 Apr 2025

• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Verve Moves Toward Lilly Opt-In For PCSK9 Program With Phase Ib Results

14 Apr 2025

• By Alaric DeArment

The company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

10 Apr 2025

• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

What Is Fuelling Cell And Gene Therapies In India?

07 Apr 2025

• By Vibha Ravi

Bharat Biotech is the latest entrant in India’s cell and gene therapy space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

17 Apr 2025

• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.